Foundayo (orforglipron) coverage guide: the first non-peptide oral GLP-1 for weight loss — access, pricing, PA criteria, and payer coverage

On April 1, 2026, the FDA approved orforglipron (Foundayo, Eli Lilly), a once-daily oral small-molecule GLP-1 receptor agonist, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Foundayo is the first non-peptide oral GLP-1 receptor agonist approved for obesity and the first new molecular entity approved under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program — cleared just 50 days after filing.

The approval creates a new category in the GLP-1 landscape: a pill that can be taken at any time of day with no food or water restrictions, dispensed through retail pharmacies and LillyDirect, at a self-pay price point ($149/month starting dose) significantly below injectable GLP-1s. For access teams, the immediate questions are payer coverage status, prior authorization requirements, specialty pharmacy routing, and how Foundayo fits alongside Wegovy, Zepbound, and other weight-management therapies.

This guide is for market-access professionals, payer strategists, pharmacists, and healthcare providers who need to understand Foundayo's regulatory status, clinical evidence, formulary positioning, prior authorization landscape, and patient affordability pathways.

Short answer

How Foundayo differs from other GLP-1 weight-loss therapies

Foundayo's positioning: an oral GLP-1 with no administration restrictions (unlike oral Wegovy, which requires dosing on an empty stomach with ≤4 oz water and a 30-minute wait before eating), priced substantially below injectables for self-pay patients. The trade-off is lower efficacy compared to semaglutide injection and tirzepatide at maximum doses.

Clinical evidence: ATTAIN program

The FDA approval was based on the phase 3 ATTAIN clinical trial program, which evaluated orforglipron in adults with obesity or overweight with weight-related comorbidities.

ATTAIN-1 (NCT trial):

• Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with ≥1 weight-related comorbidity
• Foundayo at highest dose (17.2 mg): average weight loss of ~12.4% (approximately 27 pounds) over 72 weeks
• Improvements in cardiovascular risk factors: waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure
• Common adverse events: nausea, diarrhea, vomiting, constipation — typical GLP-1 class effects
• Most GI events occurred during dose titration and were mild to moderate

Key access implication: The ATTAIN trial program did not specifically enroll patients who failed prior GLP-1 therapy, which means payers are unlikely to impose step therapy requiring injectable GLP-1 failure before approving Foundayo. However, some plans may still require documented BMI and lifestyle modification history.

Prior authorization requirements

Because Foundayo launched in April 2026, most commercial payers are still establishing formulary positions. Early data from PrescriberPoint indicates that several plans have added Foundayo with PA requirements.

Common PA criteria

Prior authorization for Foundayo typically requires:

1. BMI documentation: BMI ≥30 (obesity) or BMI ≥27 (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or other qualifying condition)
2. Lifestyle modification documentation: evidence of participation in a reduced-calorie diet and increased physical activity program
3. Exclusion of pregnancy: Foundayo is contraindicated in pregnancy
4. ICD-10 codes:
   • E66.01 (Morbid severe obesity due to excess calories)
   • E66.09 (Other obesity)
   • E66.3 (Overweight)
   • Z68.4x (Body mass index 40+ adult)
   • Z68.3x (Body mass index 30–39 adult)

Payer-specific notes

Aetna: PA forms for Foundayo are available as of May 2026. Initial criteria mirror the FDA label (BMI thresholds + comorbidities). Aetna's medical exception process applies when the drug is non-formulary.

Cigna: Early coverage data shows Foundayo covered on 4 commercial plans as of late April 2026, with PA requirements varying by plan tier.

Humana: PA form available as of May 2026. Humana's standard GLP-1 PA criteria (BMI + comorbidities + lifestyle documentation) apply.

OptumRx / UnitedHealthcare: Foundayo is being reviewed for formulary placement. PA and step therapy requirements are expected to mirror those for other GLP-1 weight-loss therapies.

PA timelines for Foundayo typically run 7–21 days from submission to decision. The most common delay is at the submission step — incomplete BMI documentation or missing lifestyle modification records are the top reasons for initial PA denial.

Access barrier context: As of early 2026, more than 16 million people in the U.S. lack insurance coverage for GLP-1 drugs. Many insurers classify weight-loss drugs as "not medically necessary" or label them as "lifestyle" or "cosmetic" treatments. Plan-specific riders are generally required for coverage. Access teams should verify formulary status before submitting PA, as a plan that excludes GLP-1 weight-loss drugs will deny PA regardless of documentation quality.

Early formulary data (PrescriberPoint / MMIT, May 2026): Foundayo is covered on 5 of the top 10 commercial plans for at least one plan variant. 0 of the 5 require PA on the plans tracked so far, but this data is still maturing and PA requirements are expected to tighten as formulary committees complete their reviews. Cigna shows Foundayo covered on 4 commercial plan variants. Coverage data is updated monthly and should be checked at point of prescribing.

Medicare access

Medicare Part D statutory exclusion

Historically, Medicare Part D has statutorily excluded coverage for drugs indicated for "anorexia, weight loss, or weight gain." This means GLP-1 drugs indicated solely for weight management (including Foundayo) are excluded from standard Part D coverage.

The Medicare BALANCE/GLP-1 Bridge demonstration

CMS has established the Medicare GLP-1 Bridge demonstration (also referred to as the BALANCE model), which takes effect July 1, 2026. Key details:

• Eligible drugs: All formulations of Foundayo, Wegovy, and the KwikPen formulation of Zepbound
• Copay: $50/month for eligible Medicare Part D beneficiaries
• Manufacturer net price: CMS negotiated a $245 net price per 30-day supply for all model drugs in 2027
• Eligibility criteria: Provider must attest that the beneficiary is being prescribed the drug for weight reduction and ongoing maintenance, and the patient must meet one of three clinical categories:
  1. BMI ≥35 with at least one weight-related comorbidity, OR
  2. BMI ≥30 with at least two weight-related comorbidities, OR
  3. BMI ≥27 with a diagnosis of prediabetes or other specified metabolic criteria
• PA required: Yes, via the demonstration's specific PA process
• Duration: The demonstration runs July 1, 2026 through December 31, 2027 (originally through December 2026; CMS extended the Bridge in April 2026 after delaying the longer-term BALANCE Part D model)

This is a major access development. Access teams should identify Medicare Part D patients who qualify and prepare PA submissions ahead of the July 1, 2026 launch date.

Medicaid coverage

Medicaid coverage for GLP-1 weight-loss drugs varies significantly by state. Most state Medicaid programs exclude coverage for weight-loss drugs, though some cover GLP-1s for type 2 diabetes (not the obesity indication). Foundayo is not yet approved for type 2 diabetes — Lilly has stated plans to submit a diabetes indication to the FDA sometime in 2026.

Access teams should:

• Check the specific state Medicaid formulary for orforglipron coverage
• Monitor whether states update preferred drug lists (PDLs) following the diabetes indication submission
• Be prepared for Medicaid PA denials in states that exclude weight-loss drugs

Patient affordability and savings programs

Foundayo Savings Card (commercial insurance)

• Eligible commercially insured patients may pay as little as $25/month
• Covers up to 10 fills per year
• Not valid for government-insured patients (Medicare, Medicaid, Tricare, VA)
• Patients enrolled in Alternate Funding Programs (AFPs) are not eligible

LillyDirect self-pay

• No insurance required
• Starting at $149/month for the 0.8 mg starting dose
• Dose-tiered pricing: $149/mo (0.8 mg), $199/mo (2.5 mg), $299/mo (5.5 mg, 9 mg, 14.5 mg, 17.2 mg with Self-Pay Journey Program)
• Free home delivery
• The $299 price for 14.5 mg and 17.2 mg doses requires refill within 45 days of the previous fill (Self-Pay Journey Program); missing the window increases the price to $349/month
• Telehealth partners (Ro, etc.) also offer Foundayo with PA submission support, typically at $149/month plus a platform fee

Merck vs. Lilly patient support

Foundayo is a Lilly product. Lilly's patient support infrastructure is built around LillyDirect, the Foundayo savings card, and the Foundayo Self-Pay Journey Program. The key difference from injectable GLP-1 support programs: Foundayo is dispensed through retail pharmacies (not specialty pharmacies), which simplifies fulfillment but also means patients are more likely to face retail-level PA friction.

Specialty pharmacy routing

Unlike injectable GLP-1s (Wegovy, Zepbound) that route through specialty pharmacies or limited distribution networks, Foundayo is available through:

1. LillyDirect Pharmacy: direct-to-patient home delivery, self-pay or with insurance processing
2. Retail pharmacies: broad availability through major chains and independent pharmacies
3. Telehealth platforms: Ro, and potentially others, offer direct prescribing and fulfillment

This distribution model means access teams do not need to navigate specialty pharmacy prior authorization workflows for most patients. The PA is between the prescriber and the payer, not the specialty pharmacy.

Dose titration and PA implications

Foundayo requires a titration schedule that affects PA duration and refill management:

PA implications:

• Some payers may authorize the full titration series in a single PA; others may require reauthorization at each dose level
• Access teams should document titration tolerance at each step, as reauthorization may require evidence the patient tolerated the prior dose
• Quantity limits may apply (typically one 30-day supply per fill)

Drug interactions

Foundayo is metabolized by CYP3A enzymes. Key interactions:

• Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort): may decrease orforglipron exposure; dosage modification may be required
• Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): may increase orforglipron exposure; dosage modification may be required
• Prescribers should consult the full prescribing information for comprehensive interaction guidance

What to monitor next

1. Diabetes indication submission: Lilly has stated plans to submit Foundayo for type 2 diabetes approval in 2026. Approval would open Medicaid and Medicare Part D coverage through standard (not demonstration) pathways.

2. Formulary decisions: Major PBMs (CVS Caremark, Express Scripts, OptumRx) are expected to issue formulary updates for Foundayo in Q3–Q4 2026. Watch for step therapy requirements (e.g., requiring Foundayo before injectable GLP-1s or vice versa).

3. BALANCE demonstration enrollment data: CMS will publish utilization data from the Medicare GLP-1 Bridge demonstration, which will signal how aggressively Medicare is covering oral GLP-1s.

4. Competitor launches: Oral Wegovy (semaglutide tablets) was approved in December 2025. Head-to-head formulary positioning between Foundayo and oral Wegovy will shape PA criteria and step therapy protocols.

5. Compounding and counterfeit risk: As with other GLP-1s, unauthorized compounded orforglipron products may appear. Lilly and FDA are expected to issue enforcement guidance.

Sources

• FDA. Novel Drug Approvals for 2026. fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
• FDA. FDA Approves First New Molecular Entity Under National Priority Voucher Program (April 1, 2026). fda.gov/news-events/press-announcements
• Eli Lilly. FDA Approves Lilly's Foundayo (orforglipron) News Release (April 1, 2026). investor.lilly.com
• Eli Lilly. Lilly and U.S. Government Agree to Expand Access to Obesity Medicines (November 6, 2025). lilly.gcs-web.com
• KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid (2026). kff.org/medicare
• Drugs.com. How Much Does Foundayo Cost? (April 8, 2026). drugs.com
• Nature Reviews Drug Discovery. FDA Approves GLP-1 Pill for Obesity (2026). nature.com/articles/d41573-026-00059-9
• MedCentral. Orforglipron and Its Unique Delivery Method Expand Obesity Treatment Options (April 2026). medcentral.com